Pharma Weighs Options for Locating IP: Transfer Pricing Report

Hello and welcome to the Transfer Pricing Report. I’m Caleb Harshberger, and this week we’re looking at the pharmaceutical industry’s options for keeping intangibles overseas as companies race to show the Trump administration that they’re bringing more manufacturing to the US.

President Donald Trump’s tariff policy is prompting large pharma companies to promise investments in US manufacturing, but it might let them keep the crown jewels—their intellectual property—overseas, practitioners told me.

And that can come with big opportunities for tax planning.

Since the initial tariffs were announced, big pharma businesses have pledged billions of dollars toward new US manufacturing ...